P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 13.93 CNY -3.4% Market Closed
Market Cap: 13.2B CNY

Pacific Shuanglin Bio pharmacy Co Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pacific Shuanglin Bio pharmacy Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Pre-Tax Income
ÂĄ640.2m
CAGR 3-Years
8%
CAGR 5-Years
31%
CAGR 10-Years
21%
Beigene Ltd
HKEX:6160
Pre-Tax Income
-ÂĄ4.2B
CAGR 3-Years
24%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Pre-Tax Income
ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Pre-Tax Income
-ÂĄ501.1m
CAGR 3-Years
26%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Pre-Tax Income
ÂĄ67.5m
CAGR 3-Years
-69%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Pre-Tax Income
-ÂĄ142.5m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
13.2B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
24.69 CNY
Undervaluation 44%
Intrinsic Value
Price
P

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Pre-Tax Income?
Pre-Tax Income
640.2m CNY

Based on the financial report for Sep 30, 2025, Pacific Shuanglin Bio pharmacy Co Ltd's Pre-Tax Income amounts to 640.2m CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
21%

Over the last year, the Pre-Tax Income growth was -32%. The average annual Pre-Tax Income growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been 8% over the past three years , 31% over the past five years , and 21% over the past ten years .

Back to Top